2022 American Society of Hematology (ASH) Annual Meeting Recap
New Developments in Lymphoma
by Caleigh
1y ago
The 2022 American Society of Hematology (ASH) Annual Meeting marked the 64th year in a row that hematology professionals gathered to discuss the latest research and updates in blood cancers and blood disorders. ASH is the world’s largest professional organizations made up of physicians and scientists with a keen interest in tackling blood diseases. Over ..read more
Visit website
American Society of Hematology (ASH) 2022 Involvement: The Lymphoma Epidemiological Outcomes (LEO) Cohort
New Developments in Lymphoma
by Caleigh
1y ago
At Weill Cornell Medicine (WCM) and NewYork-Presbyterian, we are proud to partner with the Lymphoma Epidemiological Outcomes (LEO) Cohort for a variety of research projects aimed to change the way we understand and manage lymphoma, a broad category which encompasses nearly 80 different distinct disease types. The LEO Cohort is the largest, most diverse study ..read more
Visit website
Mantle Cell Lymphoma: Research, Treatment, and Support at Weill Cornell Medicine
New Developments in Lymphoma
by Caleigh
2y ago
Mantle cell lymphoma (MCL) is an uncommon form of non-Hodgkin lymphoma that is tied to genetic changes in the white blood cells which makes them continually divide and accumulate within the body. MCL affects approximately 4,000 new patients each year. This form of blood cancer is unique and behaves differently in different people, meaning there ..read more
Visit website
2021 American Society of Hematology (ASH) Annual Meeting
New Developments in Lymphoma
by Caleigh
2y ago
For the 63rd year in a row, the American Society of Hematology (ASH) hosted the Annual Meeting & Exposition. ASH is one of the world’s largest professional organizations made up of physicians and scientists with a keen interest in tackling blood diseases. This annual ASH conference is attended by approximately 25,000 participants, mainly hematology professionals, who gather ..read more
Visit website
ASCO 2021 – Lymphoma Updates
New Developments in Lymphoma
by lindseyhemonc
2y ago
The American Society of Clinical Oncology (ASCO) is the world’s leading organization for physicians and oncology professionals caring for people with cancer. The 2021 Annual Meeting was hosted virtually, connecting oncology professionals from around the world to discuss the newest, state-of-the-art research and treatment updates. The Weill Cornell Lymphoma Program team is always proud of ..read more
Visit website
Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study
New Developments in Lymphoma
by lindseyhemonc
3y ago
At the 2020 Annual Meeting of the American Hematology Society (ASH), the Weill Cornell Medicine mantle cell lymphoma research team presented the 7-year long-term outcome analysis of the first study of a non-chemotherapy frontline treatment regimen with lenalidomide plus rituximab as induction and maintenance therapy for mantle cell lymphoma (MCL).   The multi-center phase 2 study, led by study ..read more
Visit website
Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)
New Developments in Lymphoma
by lindseyhemonc
3y ago
Today, at the 2020 Annual Meeting of the American Hematology Society (ASH), the Weill Cornell Medicine T-cell lymphoma research team reported the outcome of the first phase 2 study evaluating the novel combination of oral azacitidine plus CHOP as initial treatment for patients with peripheral T-cell lymphoma (PTCL). This multi-center phase 2 study, led by Dr. Jia ..read more
Visit website
2020 American Society of Hematology (ASH) Annual Meeting
New Developments in Lymphoma
by lindseyhemonc
3y ago
The American Society of Hematology (ASH) is the world’s largest professional society serving clinicians and scientists who work to conquer blood diseases. This year the 62nd ASH Annual Meeting & Exposition – the premier conference in malignant and non-malignant hematology – will bring together approximately 25,000 hematology professionals from around the world virtually. As always, our ..read more
Visit website
COVID-19 and Cancer: Helpful Resources for Lymphoma Patients
New Developments in Lymphoma
by lindseyhemonc
4y ago
The Weill Cornell Medicine Lymphoma Program team remains committed to supporting and protecting the health and safety of our patient community during this challenging time. With COVID-19 dominating the news and impacting our everyday lives, many people may be left wondering which sources to trust and which recommendations to follow when it comes to understanding ..read more
Visit website
Precision Medicine Combination Treatment Shows Anti-Tumor Activity in Preclinical DLBCL Models
New Developments in Lymphoma
by jacquiehemonc
4y ago
By Sucharita Mistry, PhD Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in adults. DLBCLs are aggressive and typically represent a heterogeneous collection of diseases that can be grouped into different subtypes depending on their particular genetic lesions. One such subtype, described as the C3 or EZB cluster, features alterations ..read more
Visit website

Follow New Developments in Lymphoma on FeedSpot

Continue with Google
Continue with Apple
OR